ストックスクリーナーアプリを入手
2.92
2.10%
0.06
アフターアワーズ：
2.86
-0.06
-2.05%
前日終値:
$2.86
開ける：
$3.05
24時間の取引高:
136.30K
Relative Volume:
0.30
時価総額：
$4.58M
収益：
-
当期純損益:
$-36.46M
株価収益率:
-1.2167
EPS:
-2.4
ネットキャッシュフロー:
$-30.20M
1週間 パフォーマンス:
-1.02%
1か月 パフォーマンス:
+89.61%
6か月 パフォーマンス:
+38.38%
1年 パフォーマンス:
-82.51%
1日の値動き範囲:
$2.80
$3.20
1週間の範囲:
$2.25
$3.40
52週間の値動き範囲:
$1.3137
$16.70
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
TCRT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
2.92 | 4.58M | 0 | -36.46M | -30.20M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-10-04 | 再開されました | Wells Fargo | Overweight |
Alaunos Therapeutics Inc (TCRT) 最新ニュース
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World
Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
TScan Therapeutics Appoints Jason A. Amello as Chief Financial Officer - citybiz
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider
Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance
Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology
AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology
How gene therapies can transform sickle cell disease treatment - Pharmaceutical Technology
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq
Houston biotech winds down sole clinical-stage trial, cuts 60% of staff - Fierce Biotech
Neoleukin to merge with Neurogene for $200m in cash reserves - Pharmaceutical Technology
15 Biotech Stocks Wall Street Analysts Say Are Too Cheap - Barron's
Hopewell Therapeutics raises funds for genomic medicines development - Pharmaceutical Technology
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting - StockTitan
Alaunos Therapeutics Inc (TCRT) 財務データ
収益
当期純利益
現金流量
EPS
4.44%
大文字化:
|
ボリューム (24 時間):